Management anticipates 2027 will be the low point of Boston Scientific’s current cycle. The company cut its full-year 2026 outlook after third-quarter organic sales growth came in below its prior guidance. Management expects more substantial performance improvement in 2028, with new products and restructuring identified as potential recovery supports.
Key facts
Management cut Boston Scientific's full-year outlook and expects 2027 to be the trough of the current cycle, with recovery in 2028. source
Management anticipates 2027 to be the low point of the current cycle, with more substantial performance improvements not expected until 2028. source